Ten years ago, our understanding of the molecular landscape in glioma was transformed by the first genome-wide analysis of somatic mutations in glioblastoma (GBM) and the identification of recurrent mutations in IDH1 nearly exclusively in secondary GBM (2). Here, IDH1 is linked to central nervous system cancer.